Hyundai Motor got 37,446 pre-orders for its new electric vehicle (EV) Ioniq 6 on the first day of pre-booking on Monday.
The Ioniq 6 received the most first-day pre-orders in the Korean market's car sales history, exceeding the 23,760 pre-orders that the Ioniq 5 received a year and a half ago.
The company said the high popularity of the Ioniq 6 shows Korean consumers think the new vehicle will become a game changer in the era of EVs.
A Hyundai Motor spokesman attributed the good customer response to the Ioniq 6 to its innovative interior and exterior design and excellent mileage capability, made possible because of the best-in-class aerodynamic performance and new technologies.
The Ioniq 6 has a low drag coefficient of just 0.21.
The company said the Ioniq 6 is receiving a lot of positive reviews from major media outlets in Europe and the US.


Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Disaster or digital spectacle? The dangers of using floods to create social media content
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Glastonbury is as popular than ever, but complaints about the lineup reveal its generational challenge
Gold and Silver Surge as Safe Haven Demand Rises on U.S. Economic Uncertainty
6 simple questions to tell if a ‘finfluencer’ is more flash than cash
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
BOJ Poised for Historic Rate Hike as Japan Signals Shift Toward Monetary Normalization
Yes, government influences wages – but not just in the way you might think
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Britain has almost 1 million young people not in work or education – here’s what evidence shows can change that
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



